HealthEquity (HQY)
(Delayed Data from NSDQ)
$80.98 USD
+1.22 (1.53%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $80.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.98 USD
+1.22 (1.53%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $80.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Zacks News
HealthEquity (HQY) Down 2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMN vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. HQY: Which Stock Is the Better Value Option?
NovoCure (NVCR) Jumps: Stock Rises 7.1%
by Zacks Equity Research
NovoCure (NVCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
HealthEquity (HQY) Set to Acquire WageWorks for $2 Billion
by Zacks Equity Research
HealthEquity (HQY) is set to acquire WageWorks in an all-cash deal of about $2 billion. The buyout is expected to help HealthEquity to expedite the market-wide transition to HSAs.
Is HealthEquity (HQY) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider HealthEquity (HQY).
Teladoc (TDOC) Up 22% in a Year: Will the Rally Continue?
by Zacks Equity Research
Teladoc's increasing visits and subscriptions are likely to aid revenue growth. This will further drive its share price.
Zacks.com featured highlights include: Comcast, Enterprise Products, HealthEquity and Pioneer Natural
by Zacks Equity Research
Zacks.com featured highlights include: Comcast, Enterprise Products, HealthEquity and Pioneer Natural
4 of the Best Stocks to Buy for Superb Earnings Growth
by Tirthankar Chakraborty
We select four stocks that have striking earnings growth and positive estimate revisions.
New Strong Buy Stocks for June 7th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
HealthEquity (HQY) Earnings & Revenues Top Estimates in Q1
by Zacks Equity Research
Higher revenues, solid segmental performance and expansion in margins benefit HealthEquity's (HQY) Q1 earnings.
HealthEquity (HQY) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 20.59% and 3.65%, respectively, for the quarter ended April 2019. Do the numbers hold clues to what lies ahead for the stock?
ICLR or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Down 16.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRAH vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
PRAH vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q4
by Zacks Equity Research
HealthEquity (HQY) witnesses strong HSA member growth in the fourth quarter of fiscal 2019.
PRAH vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PRAH vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HealthEquity (HQY) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
HealthEquity (HQY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors
by Zacks Equity Research
HealthEquity's (HQY) solid guidance for fiscal 2019 favors stock.
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will HealthEquity, Inc. (HQY) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in HealthEquity, Inc.
Is HealthEquity (HQY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
Teladoc Expands Services with Virtual Back Pain Treatment
by Zacks Equity Research
Teladoc's (TDOC) new addition of virtual back pain treatment will broaden its suite of products and services.
Here is Why Growth Investors Should Buy HealthEquity (HQY) Now
by Zacks Equity Research
HealthEquity (HQY) could produce exceptional returns because of its solid growth attributes.
3 Medical Services Stocks to Buy in 2019: HQY, AMEH & OPGN
by Sreyoshi Mukherjee
Here we discuss three profitable Medical Services stocks as the industry booms.